Isobavachalcone

Isobavachalcone

SCHEMBL600137

CC(C)=CCc1c(O)ccc(C(=O)/C=C/c2ccc(O)cc2)c1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 5/20 1.00
DHODH Q02127 1/20 1.00
MAOB P27338 3/20 0.81
MEN1 O00255 2/20 0.81
LMNA P02545 2/20 0.81
MAPT P10636 2/20 0.81
KMT2A Q03164 2/20 0.81
ALDH1A1 P00352 1/20 0.81
GAA P10253 1/20 0.81
CYP19A1 P11511 2/20 0.72
TYR P14679 2/20 0.72
PTGS1 P23219 2/20 0.72
PTGS2 P35354 2/20 0.72
CASP3 P42574 1/20 0.67
SENP8 Q96LD8 1/20 0.67
SENP7 Q9BQF6 1/20 0.67
SENP6 Q9GZR1 1/20 0.67
PDPK1 O15530 1/20 0.61
TTR P02766 1/20 0.61
ALOX5 P09917 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5518698 0.90 PTPN1 (0.82) PTPN1DHODHMAOBMEN1LMNA
SCHEMBL5518692 0.90 PTPN1 (0.82) PTPN1DHODHMAOBMEN1LMNA
Isocordoin SCHEMBL24075559 0.90 PTPN1 (0.81) PTPN1DHODHMAOBMEN1LMNA
Xanthoangelol SCHEMBL454823 0.90 MEN1 (1.00) PTPN1DHODHMAOBMEN1LMNA
Xanthoangelol SCHEMBL5519362 0.90 MEN1 (1.00) PTPN1DHODHMAOBMEN1LMNA
Xanthoangelol SCHEMBL5519356 0.90 MEN1 (1.00) PTPN1DHODHMAOBMEN1LMNA
SCHEMBL5515022 0.89 MEN1 (0.98) PTPN1DHODHMAOBMEN1LMNA
SCHEMBL14523853 0.89 MEN1 (0.98) PTPN1DHODHMAOBMEN1LMNA
SCHEMBL29696899 0.89 PTPN1 (0.82) PTPN1DHODHMAOBMEN1LMNA
SCHEMBL21717734 0.89 PTPN1 (0.80) PTPN1DHODHMAOBMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 508 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4714440-A2 A HEALING HERBAL-MINERAL COMPOSITION WITH ENHANCED EFFECTS Kurek, Janusz (PL) 2026-03-25 EP claimed
EP-4680720-A1 OPTIMIZED PRODUCTION OF BRANCH POINT COMPOUNDS AND DERIVATIVES USING ALTERNATIVE ISOPENTENYL DIPHOSPHATE-SUPPLYING PATHWAYS EvodiaBio ApS (DK) 2026-01-21 EP claimed
US-12529077-B2 Production of geranyl diphosphate-derived compounds Københavns Universitet (DK) 2026-01-20 US claimed
US-20250339399-A1 SUPRAMOLECULAR SELF-ASSEMBLY SYSTEM BEIJING CREATRON INSTITUTE OF PHARMACEUTICAL RES CO LTD (CN) 2025-11-06 US claimed
EP-4543220-A2 COMPOSITIONS FOR REDUCING METHANE EMISSIONS, ANIMAL FEEDS COMPRISING THEM AND THEIR USE TO REDUCE METHANE EMISSIONS Mootral Innovations Limited (GB) 2025-04-30 EP claimed
CN-119881186-A Method for measuring content of multiple components in Jiaweiqing E pill 北京同仁堂股份有限公司 2025-04-25 CN claimed
CN-119730731-A Composition for reducing methane emissions, animal feed containing same and use thereof for reducing methane emissions 莫特迩创新有限公司 2025-03-28 CN claimed
WO-2024189183-A1 OPTIMIZED PRODUCTION OF BRANCH POINT COMPOUNDS AND DERIVATIVES USING ALTERNATIVE ISOPENTENYL DIPHOSPHATE-SUPPLYING PATHWAYS EVODIABIO APS (DK) 2024-09-19 WO claimed
CN-118660707-A Supermolecule self-assembly system 北京睿创康泰医药研究院有限公司 2024-09-17 CN claimed
US-20240266187-A1 METHOD FOR ENHANCING STABILITY OF N-TYPE SEMICONDUCTOR THROUGH OXYGEN ELIMINATION TIANJIN UNIVERSITY (CN) 2024-08-08 US claimed
EP-2274411-A1 XANTHOHUMOL COMPOSITIONS AND METHODS FOR TREATING SKIN DISEASES OR DISORDERS BETAL LLC (US) 2011-01-19 EP claimed
EP-2249641-A1 NOVEL COMPOSITIONS CONTAINING XANTHOHUMOL-CYCLODEXTRIN COMPLEXES Flaxan GmbH & Co. KG (US) 2010-11-17 EP claimed
WO-2009126320-A1 XANTHOHUMOL COMPOSITIONS AND METHODS FOR TREATING SKIN DISEASES OR DISORDERS BETAL, LLC (US) 2009-10-15 WO claimed
WO-2009108379-A1 NOVEL COMPOSITIONS CONTAINING XANTHOHUMOL-CYCLODEXTRIN COMPLEXES FLAXAN GMBH & CO. KG (US) 2009-09-03 WO claimed
CN-101215229-A Bavachalcone compounds capable of resisting plant epiphyte disease SHENYANG INST OF CHEMICAL TECH (CN) 2008-07-09 CN claimed
US-20070092551-A1 Therapeutic agent TAKARA BIO INC. (JP) 2007-04-26 US claimed
EP-1623704-A1 THERAPEUTIC AGENT TAKARA BIO INC. (JP) 2006-02-08 EP claimed
WO-2004022080-A2 BUGUZHI AGENT AND COMPOSITION AND METHODS OF PREPARING AND ADMINISTERING THE SAME THE UNIVERSITY OF HONG KONG (CN) 2004-03-18 WO claimed
WO-2001001996-A9 COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING OSTEOPOROSIS UNIV WESTERN AUSTRALIA (AU) 2002-09-12 WO claimed
WO-2001001996-A1 COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING OSTEOPOROSIS UNIVERSITY OF WESTERN AUSTRALIA (AU) 2001-01-11 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12529077-B2 Production of geranyl diphosphate-derived compounds GGPS1, OGA, GBA3 PTPN1 3536/4885DHODH 163/4885MAOB 1375/4885
US-20250339399-A1 SUPRAMOLECULAR SELF-ASSEMBLY SYSTEM S100A8, TP53, AQP1 PTPN1 2775/4885DHODH 1206/4885MAOB 4411/4885
US-20070092551-A1 Therapeutic agent FABP4, GPR119, IAPP PTPN1 1950/4885DHODH 3351/4885MAOB 4382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.